Get started
Author

Hans Bigalke

Observed names: Bigalke Hans, H Bigalke, H. Bigalke
OpenAlex ID: A5020147732
The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves
2006 · Stefan Mahrhold, Andreas Rummel, et al. · FEBS Letters · 315
Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences
1997 · Hilke Göschel, Kai Wohlfarth, et al. · Experimental Neurology · 314
Synaptotagmins I and II Act as Nerve Cell Receptors for Botulinum Neurotoxin G
2004 · Andreas Rummel, Tino Karnath, et al. · Journal of Biological Chemistry · 235
The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction
2003 · Andreas Rummel, Stefan Mahrhold, et al. · Molecular Microbiology · 217
PDF
Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept
2006 · Andreas Rummel, Timo Eichner, et al. · Proceedings of the National Academy of Sciences · 179
PDF
Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation‐dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor
2009 · Andreas Rummel, Kirstin Häfner, et al. · Journal of Neurochemistry · 162
Two Carbohydrate Binding Sites in the HCC-domain of Tetanus Neurotoxin are Required for Toxicity
2003 · Andreas Rummel, Steffen Bade, et al. · Journal of Molecular Biology · 141
Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study
2002 · Wendelin Blersch, Wilhelm J Schulte-Mattler, et al. · Journal of the Neurological Sciences · 122
Botulinum A toxins: units versus units
1997 · K. Wohlfarth, Hilke Göschel, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 109
Molecular aspects of tetanus and botulinum neurotoxin poisoning
1995 · Gudrun Ahnert-Hilger, Hans Bigalke · Progress in Neurobiology · 104
Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
2004 · Steffen Bade, Andreas Rummel, et al. · Journal of Neurochemistry · 100
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure
2003 · D. Dressler, Hans Bigalke, et al. · Journal of Neurology · 85
A long-term follow-up of botulinum toxin A in cervical dystonia
2009 · B. Mohammadi, N. Buhr, et al. · Neurological Research · 81
Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner
2010 · Jasmin Strotmeier, Kwangkook Lee, et al. · Biochemical Journal · 76
The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites
2011 · Jasmin Strotmeier, Shenyan Gu, et al. · Molecular Microbiology · 65
Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells
1989 · P. Marxen, U. Fuhrmann, et al. · Toxicon · 63
Botulinum A Toxin: Dysport Improvement of Biological Availability
2001 · Hans Bigalke, Kai Wohlfarth, et al. · Experimental Neurology · 62
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins—a single cohort 4-year follow-up study
2012 · Harald Hefter, Christian Hartmann, et al. · BMJ Open · 55
PDF
Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin.
1994 · F. Bartels, H. Bergel, et al. · Journal of Biological Chemistry · 53
Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN)
2015 · Hans Bigalke, Andreas Rummel · Toxins · 52
PDF
Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay
2000 · D. Dressler, G. Dirnberger, et al. · Movement Disorders · 47
Low-Dose Treatment of Cervical Dystonia, Blepharospasm and Facial Hemispasm with Albumin-Diluted Botulinum Toxin Type A under EMG Guidance
2000 · Jens D. Rollnik, Mike Matzke, et al. · European Neurology · 47
Pharmacokinetic properties of different formulations of botulinum neurotoxin type A
2004 · Kai Wohlfarth, Knut Kampe, et al. · Movement Disorders · 44
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy
2002 · Dirk Dressler, Hans Bigalke · Movement Disorders · 43
Botulinum Toxin: Application, Safety, and Limitations
2012 · Hans Bigalke · Current topics in microbiology and immunology · 37
Works count: 69
Citation count: 3,259
H-index: 28
I10-index: 47
Year
Topic
Type